U.S. Renewable Energy Stock News

Huntington Bancshares (NasdaqGS:HBAN) reports progress on its Veritex integration, highlighting execution on recent acquisition activity. The bank cites strong retention of Cadence customers as it continues to combine acquired operations with its core franchise. Huntington accelerates its share repurchase program, with updated 2026 guidance and planned additional buybacks in 2027. The company is targeting about 5% of its shares to be retired by the end of next year and over US$500 million in...

Event driven snapshot of Lindblad Expeditions Holdings With no single headline event setting the tone today, Lindblad Expeditions Holdings (LIND) is drawing attention as investors weigh its recent share performance against current profitability, revenue mix and perceived discount to estimated value. See our latest analysis for Lindblad Expeditions Holdings. The recent 5.02% 1-day share price return and 25.30% 90-day share price return at around $17.78 sit alongside a 77.98% 1-year total...

FinVolution Group (NYSE:FINV) has put solid headline numbers on the table for FY 2025 so far, with third quarter revenue of about C¥3.5b and basic EPS of C¥2.49, set against trailing 12 month totals of roughly C¥14.0b in revenue and C¥11.05 in EPS. Over recent periods, revenue has moved from around C¥3.2b in the second quarter of 2024 to about C¥3.5b in the third quarter of 2025. Quarterly EPS has ranged between roughly C¥2.12 and C¥2.95, giving investors a clear read on how the top and...

Merck (NYSE:MRK) plans to present long-term real-world data on its HPV vaccines at EUROGIN 2026. The data cover at least 14 to 18 years of effectiveness of Gardasil 9 and Gardasil against certain HPV-related cancers. The company will also share updated incidence trends for rare HPV-associated respiratory papillomatosis. For Merck, vaccines sit alongside oncology as a key pillar of the business, and Gardasil 9 and Gardasil are among its most widely used products. Extended real-world data on...

Earlier this week, research firm Stephens upgraded Customers Bancorp’s rating on its shares from “Underweight” to “Equal Weight,” signaling a shift in its stance on the regional bank’s prospects. The upgrade highlights how external analyst opinions can quickly influence investor sentiment around Customers Bancorp’s evolving business model and risk profile. Next, we’ll examine how Stephens’ more constructive stance could influence Customers Bancorp’s existing investment narrative built around...

Celcuity (CELC) is back in focus after publishing Phase 3 VIKTORIA-1 data on its breast cancer drug candidate in the Journal of Clinical Oncology, alongside fresh analyst coverage that has drawn renewed attention from investors. See our latest analysis for Celcuity. The VIKTORIA-1 publication and recent analyst attention come after a sharp rerating, with Celcuity’s 1 year total shareholder return above 10x. Its 30 day and 90 day share price returns of 9.19% and 15.20% suggest momentum has...

Why Teladoc’s latest earnings are drawing attention Teladoc Health (TDOC) just reported quarterly revenue slightly above expectations, paired with weaker near term guidance but a larger full year outlook increase than sector peers, putting both growth and caution on investors’ radar. See our latest analysis for Teladoc Health. The mixed earnings update appears to have given Teladoc’s share price a short term lift, with a 1 month share price return of 20.65% contrasting with a 1 year total...

In early March 2026, Snowden Lane Partners announced it had adopted MSCI Wealth Manager, integrating MSCI’s multi-asset analytics, risk tools, and proposal-generation platform into its advisory ecosystem, while MSCI also appointed former Goldman Sachs executive Dinesh Gupta as chief data officer and global head of Operations. These developments, alongside MSCI’s acquisition of Compass Financial Technologies and renewed analyst enthusiasm, underscore how its data, index, and wealth management...

Earlier in March 2026, UiPath reported fourth-quarter revenue of US$481.11 million and full-year revenue of US$1.61 billions, turning a prior-year net loss into net income of US$282.33 million, while also completing a US$1.00 billions buyback and authorizing a new US$500 million repurchase program. UiPath also deepened its alliance with Deloitte through the Agentic ERP offering and support for a Deloitte SAP AI & Innovation Center in EMEA, underscoring how agentic automation and AI...

Pfizer (NYSE:PFE) reported positive randomized Phase 2 results for atirmociclib, its next generation CDK4 inhibitor, in advanced or metastatic breast cancer. The company also reported positive Phase 2 data for tilrekimig, a trispecific antibody, in moderate to severe atopic dermatitis. These readouts highlight progress in Pfizer’s late stage pipeline across oncology and immunology at a key point in its corporate transition. For investors watching NYSE:PFE, these back to back data readouts...

Dow Inc. recently took part in a fireside chat at the 2026 J.P. Morgan Industrials Conference in Washington, D.C., offering investors a webcast, replay, and transcript of management’s latest commentary. This appearance comes as multiple research firms have upgraded their views on Dow, highlighting potential benefits from geopolitical supply chain shifts for North American chemical producers. With that backdrop, we’ll now examine how rising analyst confidence tied to expected supply chain...

Fifth Third Bancorp has recently declared cash dividends on its common stock and multiple preferred series, while rolling out new in‑app money‑management tools and confirming leadership appointments tied to its Comerica acquisition. Together, these moves highlight the bank’s emphasis on shareholder payouts, digital engagement and expansion into key Western and Southwestern markets. Next, we’ll examine how Fifth Third’s expanded mobile budgeting features may influence its existing investment...

Recent share performance and business snapshot Tecnoglass (TGLS) has drawn fresh attention after a mixed stretch in its share performance, with gains over the past week but negative returns over the past month and past 3 months. For context, Tecnoglass operates an architectural glass and windows business with revenue of US$983.61m and net income of US$159.57m, primarily serving commercial and residential construction markets across the United States, Colombia, Panama, and other regions. See...

Lam Research has been named one of the 2026 World's Most Ethical Companies by Ethisphere. This is the company's fourth consecutive inclusion on the list. Lam is the only wafer fabrication equipment provider to receive this recognition in 2026. For investors tracking Lam Research, ticker NasdaqGS:LRCX, this ethics recognition comes with the stock at a share price of $226.47. The company has seen a 5.2% return over the past week and a 22.4% return year to date. The 1 year and 3 year returns...

In early 2026, GE Aerospace and Palantir expanded their multi-year partnership to deploy agentic AI across U.S. Air Force readiness and GE’s production system, alongside GE Aerospace committing over US$1.00 billion in fresh U.S. manufacturing and supplier investments and plans to hire 5,000 additional workers this year. This combination of AI-enabled maintenance, supply chain automation, and large-scale domestic capacity spending highlights how GE Aerospace is tying software, manufacturing,...

Why Ulta Beauty Stock Is On Investors’ Radar Ulta Beauty (ULTA) has drawn attention after a recent share price pullback, with the stock showing a 19% decline over the past week, 23% over the past month, and 11% over the past 3 months. See our latest analysis for Ulta Beauty. The recent share price pullback, including a 23.5% 30 day share price return and 15.6% year to date share price return, contrasts with Ulta Beauty’s 52.1% one year total shareholder return. This suggests sentiment has...

If you are wondering whether Alexandria Real Estate Equities is attractively priced at its recent levels, you are not alone. This article focuses squarely on what the current share price might imply about value. The stock last closed at US$49.40, with a 3.2% decline over 7 days, a 5.9% decline over 30 days, a 0.9% gain year to date, and a 46.6% decline over the past year. Recent coverage has focused on Alexandria Real Estate Equities because investors are reassessing listed real estate and...

In the past quarter, Flowers Foods, Inc. recorded a large non-cash impairment charge on intangible assets, prompting investors to reassess its near-term outlook and risk profile. Despite this accounting setback, the company’s Dave’s Killer Bread brand continues to gain share in the organic bread category, highlighting the strength of its premium, health-focused portfolio. We’ll now examine how the sizable non-cash impairment, alongside resilience in Dave’s Killer Bread, affects Flowers...

In recent weeks Toll Brothers has rolled out or opened multiple luxury home communities and new designs across regions including Washington, California, Texas, Florida, Pennsylvania, Georgia, Nevada, Colorado, North Carolina, Utah, and Massachusetts, while also approving a quarterly US$0.26 dividend per share, its sixth consecutive annual increase. This combination of broad-based product expansion into higher-priced, amenity-rich communities and a steady dividend lift underscores the...

Blackbaud (BLKB) just rolled out its Development Agent to Raiser’s Edge NXT customers in the U.S., introducing an AI-powered teammate that can autonomously manage donor outreach under human oversight. See our latest analysis for Blackbaud. Despite rolling out the Development Agent and broadening its AI toolkit, Blackbaud’s 30 day share price return of 10.47% and year to date share price return of 26.18% decline sit alongside a 1 year total shareholder return of 31.23% decline. This points to...

For investors wondering whether JPMorgan Chase at around US$286.89 is still offering value or if most of the opportunity is already priced in, this article explores what the current share price might indicate. The stock is roughly flat over the past week with a 0.6% decline, while the 30-day and year-to-date returns of 5.2% and 11.9% declines contrast with a 24.6% gain over 1 year and 135.9% over 3 years. Recent coverage has focused on JPMorgan Chase as a bellwether for large US banks, with...

If you are wondering whether Viking Therapeutics at US$35.53 is still attractively priced or already reflecting high expectations, the next sections will walk through what the numbers suggest about its current valuation. The stock has posted returns of 2.5% over the last 7 days, 22.5% over the last 30 days, 0.3% year to date and 20.6% over the last year. This naturally raises questions about how much future upside or risk is now embedded in the price. Recent share price moves have been...

Malaysia's anti graft agency has opened a corruption and fraud probe into a major chip design agreement between Arm Holdings (NasdaqGS:ARM) and the Malaysian government. The investigation focuses on a 10 year contract involving substantial payments to Arm in exchange for chip design plans for local manufacturers. Several former ministers and officials in Malaysia have been questioned as part of the inquiry, which brings regulatory and reputational scrutiny to the deal. For you as an...

What recent performance tells you about NextNav stock NextNav (NN) has attracted fresh attention after recent price moves. The stock closed at US$16.87 and has shown positive returns over the past week, month, and past 3 months, as well as over the past year. See our latest analysis for NextNav. The share price momentum over the past week and month sits on top of a much stronger total shareholder return over one and three years. This suggests that sentiment around NextNav’s growth potential...